Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep704 | Growth hormone IGF axis - basic | ECE2016

Concomitant medication in growth hormone (GH)-treated patients with adult GH deficiency (AGHD): an analysis from NordiNet® International Outcome Study (IOS)

Hoybye Charlotte , Pournara Effie , Pedersen Birgitte Tonnes , Jorgensen Jens Otto Lunde

Introduction: Patients with AGHD receiving GH often have comorbidities requiring concomitant treatment. We evaluated patterns of concomitant medication use relative to GH therapy initiation in patients with AGHD.Methods: Patients with AGHD with data on concomitant medications enrolled in NordiNet® IOS (NCT00960128), an international, non-interventional study, receiving GH (Norditropin®, Novo Nordisk A/S, Denmark) therapy w...

ea0022p508 | Growth factors | ECE2010

Insulin resistance induced by GH is transient and reversible: glucose clamp studies during different ambient GH levels in GH-deficient adults

Krusenstjerna-Hafstrom Thomas , Moller Niels , Christiansen Jens Sandahl , Jessen Niels , Jorgensen Jens Otto Lunde

Background: The impact of GH on insulin sensitivity is ambiguous since both long standing GH-deficiency as well as acute GH exposure and prolonged GH-excess are associated with insulin resistance.Aim: To test the hypotheses that the insulin antagonistic effect of GH i) is dynamic and depend on ambient GH levels and ii) subsides gradually with time after GH exposure.Methods: Eight GHDA participated in a randomised crossover study. E...

ea0056gp190 | Pituitary / Growth Hormone ' IGF Axis | ECE2018

Insulin sensitivity improves after disease control in acromegaly irrespective of treatment modality and despite an increase in intrahepatic lipid content: data from an investigator-initiated prospective trial

Arlien-Soborg Mai C , Dal Jakob , Madsen Michael , Hogild Morten , Jessen Niels , Jorgensen Jens Otto Lunde

Background: Active acromegaly induces insulin resistance despite a lean phenotype, both of which reverse by curative surgery. The impact of somatostatin analogue treatment on insulin sensitivity is less certain and may be offset by its anti-lipogenic effects.Aim: To study insulin sensitivity, body composition and extopic lipid content in newly diagnosed patients with acromegaly before and ≥6 months after successful surgical or medical treatment.</p...

ea0049gp181 | Pituitary | ECE2017

Targeting either GH or IGF-I levels during somatostatin analogue treatment in patients with acromegaly: A randomized, investigator-initiated multicenter study

Dal Jakob , Klose Marianne , Heck Ansgar , Andersen Marianne , Kistorp Caroline , Nielsen Eigil Husted , Bollerslev Jens , Feldt-Rasmussen Ulla , Jorgensen Jens Otto Lunde

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

ea0014p67 | (1) | ECE2007

Intravenous constant ghrelin infusion in healthy young men: sustained cardiovascular effects of supraphysiological ghrelin levels

Vestergaard Esben Thyssen , Andersen Niels Holmark , Hansen Troels Krarup , Rasmussen Lars Melholt , Moller Niels , Sorensen Keld , Sloth Erik , Christiansen Jens Sandahl , Jorgensen Jens Otto Lunde

Objective: The short-term cardiovascular effects of continuous ghrelin infusion in healthy humans remain to be studied.Methods: Fifteen healthy, young and normal-weight men volunteered to participate in a randomized double-blind, placebo-controlled cross-over study. The local ethics committee approved the study. We used a constant infusion of human ghrelin at a rate of 5 pmol/kg body weight per minute for 180 minutes and measured peak left ventricular my...